News & Events about Bridgebio Pharma Inc.
BridgeBio Pharma, Inc. (NASDAQ:BBIO Get Rating) CEO Neil Kumar sold 120,000 shares of the companys stock in a transaction that occurred on Thursday, January 5th. The stock was sold at an average price of $7.67, for a total value of $920,400.00. Following the transaction, the chief ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO Get Rating)s share price fell 5.9% on Friday following insider selling activity. The stock traded as low as $7.21 and last traded at $7.23. 6,504 shares were traded during trading, a decline of 99% from the average session volume of 1,121,127 shares. The stock had...
PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the 41st Annual J.P. Morgan...
BridgeBio Pharma Inc (NASDAQ: BBIO) shares are trading higher by 16.77% to $7.87 Thursday afternoon after the company initiated its CALIBRATE Phase 3 study of Encaleret.
What Else?
read more...
- The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects of encaleret to standard of care on blood and urinary calcium concentrations over a 24 week treatment period in patients with autosomal dominant hypocalcemia type 1 (ADH1) - The ...